Piramal Pharma Ltd Stock Price Today (NSE: PPLPHARMA)
Fundamental Score
Piramal Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Piramal Pharma Ltd share price today is ₹163.35, down 0.20% on NSE/BSE as of 17 June 2026. Piramal Pharma Ltd (PPLPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹24.56K (Cr). The 52-week high for PPLPHARMA share price is ₹220.85 and the 52-week low is ₹132.30. The company has a Return on Equity (ROE) of 1.11% and a debt-to-equity ratio of 0.60.
Piramal Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Piramal Pharma Ltd share price chart: 3.23% return over the past month. 52-week high ₹220.85, 52-week low ₹132.30.
Piramal Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹170.11 | ₹170.44 | ₹164.50 | ₹166.92 | 24.40L (Cr) | |
| ₹172.99 | ₹175.95 | ₹170.36 | ₹170.90 | 16.93L (Cr) | |
| ₹174.51 | ₹175.88 | ₹171.25 | ₹172.79 | 26.26L (Cr) | |
| ₹174.24 | ₹174.24 | ₹174.24 | ₹174.24 | 0.00 (Cr) | |
| ₹178.90 | ₹179.58 | ₹173.80 | ₹174.24 | 24.80L (Cr) | |
| ₹180.00 | ₹180.72 | ₹175.40 | ₹178.86 | 21.24L (Cr) | |
| ₹176.10 | ₹180.70 | ₹175.25 | ₹179.46 | 29.36L (Cr) | |
| ₹176.50 | ₹177.55 | ₹174.60 | ₹175.63 | 14.59L (Cr) | |
| ₹177.39 | ₹178.00 | ₹174.52 | ₹176.08 | 19.83L (Cr) | |
| ₹172.80 | ₹177.00 | ₹170.20 | ₹176.35 | 27.97L (Cr) |
Piramal Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹172.99 | ₹175.95 | ₹164.50 | ₹166.92 | -3.51% | |
| ₹161.87 | ₹196.44 | ₹157.77 | ₹172.79 | +6.75% | |
| ₹140.00 | ₹171.65 | ₹136.26 | ₹161.87 | +15.62% | |
| ₹152.62 | ₹160.54 | ₹132.30 | ₹136.54 | -10.54% | |
| ₹152.40 | ₹169.54 | ₹149.76 | ₹156.13 | +2.45% | |
| ₹172.75 | ₹185.04 | ₹148.31 | ₹154.68 | -10.46% | |
| ₹187.90 | ₹189.20 | ₹165.12 | ₹172.21 | -8.35% | |
| ₹199.76 | ₹209.25 | ₹184.20 | ₹187.21 | -6.28% | |
| ₹191.07 | ₹206.60 | ₹190.52 | ₹199.63 | +4.48% | |
| ₹183.45 | ₹209.44 | ₹182.00 | ₹191.16 | +4.20% | |
| ₹198.00 | ₹198.00 | ₹182.80 | ₹183.44 | -7.35% | |
| ₹204.10 | ₹220.85 | ₹193.25 | ₹197.03 | -3.46% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Turnaround story trading at a premium; execution risk is high.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Piramal Pharma completed the acquisition of Kenalog® from Bristol-Myers Squibb on April 1, 2026. Q3 FY26 results (ended December 31, 2025) showed a net loss of , a significant YoY decline. Revenue was down 3% YoY due to inventory destocking and slower order inflows in the CDMO business. However, the company is seeing early recovery signs with increased RFPs and order inflows.
CORE STORY (THE REAL GAME)
Piramal Pharma is a play on the Indian pharma industry's shift towards innovation and complex generics, rather than just a generics manufacturer. The market is trying to figure out if they can successfully pivot to higher-margin, higher-complexity products and services.
- Early signs of recovery in CDMO order inflows
- Strong growth in consumer healthcare segment
- Acquisition of Kenalog completed
- Sustained recovery in CDMO business
- Successful integration of Kenalog
- New product launches in consumer healthcare
- High debt/equity ratio of 0.6
- Low-interest coverage ratio of 1.52x
- Negative free cash flow over 5 years
FII decreased by 0.59%, DII increased by 0.64%. Mixed signals suggest uncertainty.
Indian pharma industry projected to reach $130 billion by 2030, but faces global pricing pressures and trade uncertainties.
No. Free Cash Flow 5Y: ₹-29.18 Cr
Piramal Pharma needs to demonstrate a sustained recovery in its CDMO business and successfully integrate the Kenalog acquisition to justify its valuation. Watch for Q4 results and management commentary on the CDMO pipeline.
Primary Thesis Risk
Failure to revive CDMO business and manage debt.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Piramal Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Piramal Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PPLPHARMA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (15.15%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Institutional Confidence (FII+DII: 45.16%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (1.11%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.45%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-539.22%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-8.83%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Interest Coverage (1.52x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-29.18 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Piramal Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Piramal Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Piramal Pharma LtdPiramal Pharma ...Selected✓ PPLPHARMA • 543635 | 2.3/100 | ₹163.35₹163 | ₹24555.44₹24555.44 | — — | 1.11%Poor 1.11% Poor | 6.45%Poor 6.45% Poor | 0.60Good 0.6 Good | — — | — — | 0.08% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Piramal Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for PPLPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.68 | ₹172.21 | 253.3x |
| FY 2024 | ₹0.14 | ₹266.25 | 1901.8x |
| FY 2022 | ₹3.09 | ₹111.96 | 36.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Piramal Pharma Ltd Dividend History
Annual cash dividends paid by PPLPHARMA — dividend yield 0.08%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹14.47 Cr |
| FY 2023 | ₹67.00 Cr |
| FY 2022 | ₹50.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Piramal Pharma Ltd Quarterly Performance
Latest quarterly metrics for PPLPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-8.83%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-539.22%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Piramal Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PPLPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Piramal Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Piramal Pharma Ltd (PPLPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Piramal Pharma Ltd
About PPLPHARMA (Piramal Pharma Ltd)
Piramal Pharma Ltd is a dynamic force within the global pharmaceutical landscape, carving a niche as an integrated solutions provider. From its strategic base in India, the company... orchestrates a multifaceted approach encompassing research, development, and the manufacturing of both active pharmaceutical ingredients (APIs) and finished dosage forms. PPLPHARMA distinguishes itself through a commitment to innovation, evident in its pursuit of novel drug delivery systems and specialized formulations designed to address unmet medical needs. This commitment extends beyond its own product portfolio, as PPLPHARMA actively engages in collaborative partnerships with pharmaceutical companies worldwide, leveraging its expertise and infrastructure to accelerate the advancement of promising therapeutic candidates. Through a relentless focus on quality and efficiency, the company is positioned as a trusted partner in the ever-evolving world of healthcare. The company's operational model is built upon a foundation of advanced manufacturing capabilities and stringent regulatory compliance. With a network of state-of-the-art facilities strategically located across various geographies, Piramal Pharma Ltd offers a seamless, end-to-end solution for pharmaceutical companies seeking to outsource key stages of their drug development and manufacturing processes. This comprehensive offering spans from early-stage research and development to late-stage commercial production, ensuring that clients receive tailored support every step of the way. PPLPHARMA emphasizes sustainability in its operations, reflecting a commitment to responsible manufacturing practices and environmental stewardship. This holistic approach, combined with its unwavering focus on customer satisfaction, solidifies the company's reputation as a reliable and ethical partner within the industry. Beyond its core contract development and manufacturing (CDMO) services, Piramal Pharma Ltd also maintains a growing portfolio of proprietary pharmaceutical products targeting specific therapeutic areas. These branded offerings are distributed through a robust global network, enabling the company to directly impact patient outcomes and improve healthcare access. PPLPHARMA’s dedication to innovation and quality is underscored by its ongoing investment in research and development, constantly exploring new avenues for therapeutic advancement and operational efficiency. The company’s forward-looking vision positions it as a key player in shaping the future of pharmaceutical manufacturing and healthcare delivery, driven by a commitment to excellence and a passion for improving lives worldwide.
Company Details
Key Leadership
Corporate Events
PPLPHARMA Share Price: Frequently Asked Questions
What is the current share price of Piramal Pharma Ltd?
Piramal Pharma Ltd (PPLPHARMA) trades at ₹163.35 on NSE and BSE. Market cap ₹24.56K (Cr). Educational data only.
What is the P/E ratio of Piramal Pharma Ltd?
Piramal Pharma Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Piramal Pharma Ltd?
Piramal Pharma Ltd has a Bull Run score of 2.3/100 based on 25+ financial parameters.
Does Piramal Pharma Ltd pay dividends?
Piramal Pharma Ltd has a dividend yield of 0.08%. Past dividends don't guarantee future payments.
What is the ROE of Piramal Pharma Ltd?
Piramal Pharma Ltd has ROE of 1.11%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Piramal Pharma Ltd?
Piramal Pharma Ltd has debt-to-equity of 0.60.
Is Piramal Pharma Ltd a good investment?
Bull Run gives Piramal Pharma Ltd a score of 2.3/100. This is not investment advice — consult a SEBI-registered advisor.